VT104 is a potent and orally active YAP/TAZ inhibitor. VT104 prevents palmitoylation of endogenous TEAD1 and TEAD3 proteins. VT104 can be used in research of cancer. In Vitro VT104 (0-1000 nM) inhibits proliferation of NF2 mutant/defective cell line. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo VT104 (0.3-3 mg/kg; p.o.; NCI-H226-tumor bearing mice) blocks growth of NF2-deficient mesothelioma xenografts . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: NCI-H226-tumor bearing mice Dosage: 0.3, 1, and 3 mg/kg Administration: Oral administration Result: Blocked NCI-H226 tumor growth in mice in dose-dependent manner. Form:Solid